Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study.
J Clin Oncol. 2011 Feb 20;29(6):726-32. 
Abstract
PURPOSE:
To
 determine whether higher physical activity after prostate cancer (PCa) 
diagnosis decreases risk of overall and PCa-specific death.
PATIENTS AND METHODS:
We
 evaluated physical activity in relation to overall and PCa mortality 
among 2,705 men in the Health Professionals Follow-Up Study diagnosed 
with nonmetastatic PCa observed from 1990 to 2008. Proportional hazards 
models were used to evaluate physical activity and time to overall and 
PCa-specific death.
RESULTS:
Among men who lived at least
 4 years after their postdiagnosis physical activity assessment, we 
documented 548 deaths, 20% of which were a result of PCa. In 
multivariable analysis, men who were physically active had lower risk of
 all-cause mortality (P(trend) < .001) and PCa mortality (P(trend) = 
.04). Both nonvigorous activity and vigorous activity were associated 
with significantly lower overall mortality. Those who walked ≥ 90 
minutes per week at a normal to very brisk pace had a 46% lower risk of 
all-cause mortality (hazard ratio [HR] 0.54; 95% CI, 0.41 to 0.71) 
compared with shorter durations at an easy walking pace. Men with ≥ 3 
hours per week of vigorous activity had a 49% lower risk of all-cause 
mortality (HR, 0.51; 95% CI, 0.36 to 0.72). For PCa-specific mortality, 
brisk walking at longer durations was suggestively inverse but not 
statistically significant. Men with ≥ 3 hours per week of vigorous 
activity had a 61% lower risk of PCa death (HR, 0.39, 95% CI, 0.18 to 
0.84; P = .03) compared with men with less than 1 hour per week of 
vigorous activity. 
Men exercising vigorously before and after diagnosis 
had the lowest risk.
CONCLUSION:
In men with PCa, 
physical activity was associated with lower overall mortality and PCa 
mortality. A modest amount of vigorous activity such as biking, tennis, 
jogging, or swimming for ≥ 3 hours a week may substantially improve 
PCa-specific survival.
 
No comments:
Post a Comment